| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2015PLoSO..1042661B |
| P356 | DOI | 10.1371/JOURNAL.PONE.0142661 |
| P932 | PMC publication ID | 4643880 |
| P698 | PubMed publication ID | 26565986 |
| P5875 | ResearchGate publication ID | 283789748 |
| P50 | author | Monika Rau | Q56985327 |
| Beat Mullhaupt | Q59676656 | ||
| Christian Hammer | Q43278867 | ||
| P2093 | author name string | Heike Bantel | |
| Andreas Geier | |||
| Johannes Schmitt | |||
| Carolin Malsch | |||
| Philip P Becker | |||
| P2860 | cites work | HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1 | Q24339505 |
| MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4 | Q24633718 | ||
| Circulating microRNAs, potential biomarkers for drug-induced liver injury | Q24656209 | ||
| Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis | Q24683768 | ||
| Liver fibrosis in overweight patients | Q28145482 | ||
| Kinetics of miR-122 expression in the liver during acute HCV infection | Q28534077 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 | ||
| Long-term follow-up of patients with NAFLD and elevated liver enzymes | Q29620024 | ||
| MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma | Q30439971 | ||
| Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis | Q30448524 | ||
| A novel and universal method for microRNA RT-qPCR data normalization | Q33468633 | ||
| Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease | Q34009053 | ||
| Haemolysis during sample preparation alters microRNA content of plasma. | Q34016595 | ||
| Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma | Q34069652 | ||
| A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease | Q34070770 | ||
| Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases | Q34142333 | ||
| Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury | Q34359266 | ||
| Circulating microRNAs and aerobic fitness--the HUNT-Study | Q34612138 | ||
| Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis | Q34778143 | ||
| Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings | Q34815796 | ||
| Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties | Q34993023 | ||
| A critical evaluation of microRNA biomarkers in non-neoplastic disease | Q35107632 | ||
| MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. | Q35652362 | ||
| miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells | Q36154926 | ||
| Identification of endogenous reference genes for RT-qPCR analysis of plasma microRNAs levels in rats with acetaminophen-induced hepatotoxicity. | Q50482117 | ||
| Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. | Q51464151 | ||
| Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. | Q51707737 | ||
| Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. | Q51799363 | ||
| Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. | Q54504030 | ||
| Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. | Q55033443 | ||
| Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease | Q60617193 | ||
| Detection of elevated caspase activation and early apoptosis in liver diseases | Q73806052 | ||
| Circulating MicroRNA-122 signature in nonalcoholic fatty liver disease and cardiovascular disease: a new endocrine system in metabolic syndrome | Q85319262 | ||
| Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases | Q36365092 | ||
| miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression | Q36747098 | ||
| The Impact of Hemolysis on Cell-Free microRNA Biomarkers | Q36872732 | ||
| Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression | Q37280624 | ||
| Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. | Q37534653 | ||
| Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease | Q37596730 | ||
| Normalization strategies for microRNA profiling experiments: a 'normal' way to a hidden layer of complexity? | Q37779506 | ||
| Role of microRNAs in hepatitis B virus replication and pathogenesis. | Q37874764 | ||
| Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases | Q38018832 | ||
| Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment | Q38020699 | ||
| Epidemiology and natural history of patients with NAFLD. | Q38080108 | ||
| MicroRNAs in fatty liver disease. | Q38336422 | ||
| Circulating microRNAs: emerging biomarkers of liver disease | Q38336433 | ||
| Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes | Q39906678 | ||
| Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. | Q42233721 | ||
| Whole-genome RT-qPCR microRNA expression profiling | Q44097859 | ||
| Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. | Q44615667 | ||
| Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases | Q46045622 | ||
| Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. | Q46124754 | ||
| A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). | Q46578297 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| biomarker | Q864574 | ||
| steatohepatitis | Q2335423 | ||
| non-alcoholic steatohepatitis | Q28692677 | ||
| P304 | page(s) | e0142661 | |
| P577 | publication date | 2015-11-13 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis | |
| P478 | volume | 10 |
| Q52664090 | A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis. |
| Q57191819 | Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders |
| Q91410544 | Cholesterol impairs hepatocyte lysosomal function causing M1 polarization of macrophages via exosomal miR-122-5p |
| Q37632907 | Circulating ECV-Associated miRNAs as Potential Clinical Biomarkers in Early Stage HBV and HCV Induced Liver Fibrosis |
| Q51249709 | Circulating levels of miR-122 and nonalcoholic fatty liver disease in pre-pubertal obese children. |
| Q58700390 | Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus |
| Q100994723 | Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis |
| Q37444289 | Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population |
| Q64104666 | Eicosapentaenoic Acid Improves Hepatic Metabolism and Reduces Inflammation Independent of Obesity in High-Fat-Fed Mice and in HepG2 Cells |
| Q61813606 | Exosomal Transmission of MicroRNA from HCV Replicating Cells Stimulates Transdifferentiation in Hepatic Stellate Cells |
| Q33807881 | Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells |
| Q47864391 | Extracellular RNAs Are Associated With Insulin Resistance and Metabolic Phenotypes |
| Q54217653 | Extracellular Vesicles as Carriers of Non-coding RNAs in Liver Diseases. |
| Q41917051 | Extracellular vesicles and ceramide: new mediators for macrophage chemotaxis? |
| Q28073703 | Function and Regulation of MicroRNAs and Their Potential as Biomarkers in Paediatric Liver Disease |
| Q41940630 | High protein/fish oil diet prevents hepatic steatosis in NONcNZO10 mice; association with diet/genetics-regulated micro-RNAs |
| Q47615586 | Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression. |
| Q98771800 | Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis |
| Q38813514 | Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? |
| Q38954546 | MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease |
| Q47947610 | MicroRNAs as biomarkers for clinical studies |
| Q38814131 | MicroRNAs in hepatic pathophysiology |
| Q52311728 | Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. |
| Q90102418 | Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers |
| Q90210121 | Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis |
| Q57173225 | Noninvasive biomarkers in NAFLD and NASH - current progress and future promise |
| Q64068370 | Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice |
| Q64075673 | Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease |
| Q64098966 | Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease |
| Q57067876 | Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease |
| Q90633551 | Specific circulating microRNAs during hepatitis E infection can serve as indicator for chronic hepatitis E |
| Q57132035 | Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model |
| Q64250366 | The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD) |
| Q92594083 | Up-Regulated MicroRNA-27b Promotes Adipocyte Differentiation via Induction of Acyl-CoA Thioesterase 2 Expression |
| Q47107195 | miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. |
| Q60961391 | miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis |
Search more.